Premium
Comprehensive evaluation of context dependence of the prognostic impact of MYCN amplification in neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project
Author(s) -
Campbell Kevin,
Shyr Derek,
Bagatell Rochelle,
Fischer Matthias,
Nakagawara Akira,
Nieto Adela Canete,
Brodeur Garrett M.,
Matthay Katherine K.,
London Wendy B.,
DuBois Steven G.
Publication year - 2019
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.27819
Subject(s) - neuroblastoma , medicine , hazard ratio , oncology , confidence interval , proportional hazards model , context (archaeology) , paleontology , genetics , biology , cell culture
Background MYCN amplification (MYCN‐A) is an established adverse prognostic factor in neuroblastoma. The extent to which the prognostic impact of MYCN‐A depends on other factors has not been fully characterized. Patients and methods Using the International Neuroblastoma Risk Group database, we constructed Cox models of overall survival (OS) to obtain hazard ratios of the effect of MYCN‐A within subgroups defined by other prognostic factors. Cox models assessed the degree to which the prognostic impact of MYCN‐A was modulated by each other covariate. We used absolute hazard ratio (HR) differences to construct classification trees to identify subgroups with greatest differential prognostic effect of MYCN‐A. Results In a cohort of 6223 patients with known MYCN status, the OS hazard ratio associated with MYCN‐A was 6.3 (95% confidence interval 5.7‐7.0, P < .001). Age at diagnosis conferred the largest HR absolute difference for MYCN‐A between subgroups (HR absolute difference 16.6; HRs for MYCN‐A of 19.6 for <18 months, 3.0 for ≥18 months). MYCN‐A remained significantly prognostic of OS after controlling for other factors, abrogating their prognostic strength. Patients whose outcome was most impacted by MYCN status were those who were <18 months, had high mitosis karrhyohexis index (MKI) and low ferritin. Conclusion The prognostic strength of MYCN‐A varies depending on which patient subgroup defined by other neuroblastoma risk factors is examined, with greatest strength in patients with otherwise favorable features. MYCN‐A has little effect within some subgroups, aiding clinical decision‐making if MYCN status cannot be assessed. Subgroups where MYCN‐A has large effect may be prioritized for agents targeting Myc family proteins.